171
Participants
Start Date
May 31, 2013
Primary Completion Date
February 28, 2014
Study Completion Date
February 28, 2014
LMF237 50/250 mg
Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
LMF237 50/500 mg
Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
Placebo
Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
Novartis Investigative Site, Chikushino-shi
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Iizuka
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Kitakyushu
Novartis Investigative Site, Koga
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Yatsushiro
Novartis Investigative Site, Yatsushiro
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Sakai
Novartis Investigative Site, Takatsuki
Novartis Investigative Site, Ageo
Novartis Investigative Site, Tokorozawa
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Edogawa-ku
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Katsushika-ku
Novartis Investigative Site, Kiyose
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Minato-ku
Novartis Investigative Site, Nerima-ku
Novartis Investigative Site, Shibuya-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Toshima-ku
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY